Olabola Awosika1,2,3,4, Misty G Eleryan1,2,3,4, Monica Rengifo-Pardo1,2,3,4, Lindsay Doherty1,2,3,4, Lisa W Martin1,2,3,4, Alison Ehrlich1,2,3,4. 1. Drs. Awosika, Rengifo-Pardo, and Ehrlich are with the Department of Dermatology, The George Washington Medical Faculty Associates in Washington, DC. 2. Dr. Martin is with the Department of Cardiology, The George Washington Medical Faculty Associates in Washington, DC. 3. Drs. Eleryan, Rengifo-Pardo, Martin, and Ehrlich are also with The George Washington University School of Medicine & Health Sciences in Washington, DC. 4. Ms. Doherty is with the Department of Epidemiology and Biostatistics, School of Public Health and Health Services, George Washington University in Washington, DC.
Abstract
Objective: International case-control studies have demonstrated that psoriasis is associated with an increased prevalence of nonalcoholic fatty liver disease (NAFLD). The purpose of the present study was to establish an association of psoriasis and NAFLD in patients attending a dermatology clinic center in the United States. Design: This was an observational, case-control study. Setting: The study setting was an outpatient dermatology clinic of the George Washington Medical Faculty Associates in Washington DC. Participants: One hundred fifty-one adult patients with psoriasis and 51 control subjects were recruited. Measurements: NAFLD was diagnosed by ultrasonography after excluding secondary causes of liver disease. Regression analysis was used to assess the associations between: 1) NAFLD and psoriasis and 2) metabolic syndrome components and NAFLD among psoriasis patients. Results: NAFLD was more prevalent in patients with psoriasis (21.2% vs. 7.8%, p<0.04). However, psoriasis was not associated with NAFLD when matching for age, sex, and body mass index (BMI) (odds ratio: 2.63, 95% confidence interval [CI]: 0.51-13.6; p=0.25). As compared to patients with psoriasis but without NAFLD, those with NAFLD were more likely to have obesity (BMI: 34.9 vs. 27.2, 95% CI: 32.4-37.5 vs. 25.9-28.5; p<0.01). NAFLD in patients with psoriasis was also associated with select components of metabolic syndrome, including hyperglycemia and hyperlipidemia. Conclusion: Our findings show there is an association of psoriasis with NAFLD. Our findings also suggest an increased presence of metabolic syndrome components in patients with psoriasis and NAFLD. Trial registry: NCT00930384.
Objective: International case-control studies have demonstrated that psoriasis is associated with an increased prevalence of nonalcoholic fatty liver disease (NAFLD). The purpose of the present study was to establish an association of psoriasis and NAFLD in patients attending a dermatology clinic center in the United States. Design: This was an observational, case-control study. Setting: The study setting was an outpatient dermatology clinic of the George Washington Medical Faculty Associates in Washington DC. Participants: One hundred fifty-one adult patients with psoriasis and 51 control subjects were recruited. Measurements: NAFLD was diagnosed by ultrasonography after excluding secondary causes of liver disease. Regression analysis was used to assess the associations between: 1) NAFLD and psoriasis and 2) metabolic syndrome components and NAFLD among psoriasispatients. Results: NAFLD was more prevalent in patients with psoriasis (21.2% vs. 7.8%, p<0.04). However, psoriasis was not associated with NAFLD when matching for age, sex, and body mass index (BMI) (odds ratio: 2.63, 95% confidence interval [CI]: 0.51-13.6; p=0.25). As compared to patients with psoriasis but without NAFLD, those with NAFLD were more likely to have obesity (BMI: 34.9 vs. 27.2, 95% CI: 32.4-37.5 vs. 25.9-28.5; p<0.01). NAFLD in patients with psoriasis was also associated with select components of metabolic syndrome, including hyperglycemia and hyperlipidemia. Conclusion: Our findings show there is an association of psoriasis with NAFLD. Our findings also suggest an increased presence of metabolic syndrome components in patients with psoriasis and NAFLD. Trial registry: NCT00930384.
Authors: Luca Miele; Selenia Vallone; Consuelo Cefalo; Giuseppe La Torre; Carmine Di Stasi; Fabio M Vecchio; Magda D'Agostino; Maria L Gabrieli; Vittoria Vero; Marco Biolato; Maurizio Pompili; Giovanni Gasbarrini; Gianludovico Rapaccini; Pierluigi Amerio; Clara De Simone; Antonio Grieco Journal: J Hepatol Date: 2009-06-26 Impact factor: 25.083
Authors: Peter Rosenberg; Hanna Urwitz; Anders Johannesson; Anne-Marie Ros; Johan Lindholm; Nils Kinnman; Rolf Hultcrantz Journal: J Hepatol Date: 2007-02-15 Impact factor: 25.083
Authors: Iris González-Villanueva; Cristina DeGracia; Mariana Planells; Inés Poveda; Pedro Álvarez; Luca Schneller-Pavalescu; Isabel Betlloch; Gregor B E Jemec; Jose M Ramos; Jose C Pascual Journal: Acta Derm Venereol Date: 2020-08-18 Impact factor: 3.875
Authors: Julita Anna Krahel; Anna Baran; Tomasz W Kamiński; Magdalena Maciaszek; Iwona Flisiak Journal: J Clin Med Date: 2020-03-26 Impact factor: 4.241
Authors: Abimbola Adenote; Igor Dumic; Cristian Madrid; Christopher Barusya; Charles W Nordstrom; Libardo Rueda Prada Journal: Can J Gastroenterol Hepatol Date: 2021-04-15